Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05406037

Biomarkers for Invasive Mucormycosis

Sponsor: University Hospital, Lille

View on ClinicalTrials.gov

Summary

Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization. Prompt initiation of adequate antifungal therapy is critical for treating mucormycosis. Early diagnostic is therefore essential. The presence in the Mucorales' cell wall of uncommon monosaccharides open interesting perspectives for the development of specific diagnostic biomarkers. This study evaluate a diagnostic test for mucormycosis in a cohort of patients with MM and in control groups (high-risk patients without MM and patients with another IFI).

Official title: Diagnostic Marker of Mucormycosis : Development and Evaluation of a Diagnostic Assay on a Cohort of Sera

Key Details

Gender

All

Age Range

3 Years - 64 Years

Study Type

OBSERVATIONAL

Enrollment

100

Start Date

2023-11-29

Completion Date

2026-07

Last Updated

2025-12-26

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Venous sample

at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day

Locations (1)

University Hospital of Lille

Lille, Hauts-de-France, France